{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:37:22Z","timestamp":1787236642587,"version":"build-2736575974"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020992","name":"French National Health Insurance Fund","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020992","id-type":"DOI","asserted-by":"crossref"}]},{"name":"French National Agency for Medicines and Health Products Safety"},{"name":"Health Product Epidemiology Scientific Interest Group EPI-PHARE"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dostarlimab, a PD-1 inhibitor, was approved in Europe as monotherapy for patients with advanced or recurrent mismatch repair-deficient endometrial cancer, based on the phase I GARNET study. As real-world data remain limited, this study aimed to describe the characteristics and survival outcomes of patients treated in routine clinical practice. Using the French National Health Data System (SNDS), a cohort of all patients who received dostarlimab monotherapy through the French early access program between November 3, 2020 and December 10, 2021 was identified and followed until death, or end of the study period (December 31, 2025). Overall survival (OS), time to treatment discontinuation (TTD), and real-world progression-free survival (rwPFS) were estimated using the Kaplan-Meier method. Severe adverse events were identified based on hospital discharge diagnosis. Among 148 women included, the median age was 71\u2009years (interquartile range: 63-76). Median OS was 17.0\u2009months (95% confidence interval, 13.0-31.0), while median TTD and rwPFS were 4.0 (4.0-6.0) and 9.0 (7.0-12.0) months, respectively. During dostarlimab exposure, 9.5% of patients reported severe digestive adverse events, and 8.1% anemia. Our findings reported less favorable outcomes than in GARNET, and confirm the importance of complementing clinical trial data with real-world data to better assess the effectiveness and safety of innovative treatments across broader, unselected populations.<\/jats:p>","DOI":"10.1093\/oncolo\/oyag316","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:17:56Z","timestamp":1786965476000},"source":"Crossref","is-referenced-by-count":0,"title":["Use, survival, and adverse events of dostarlimab monotherapy in advanced or recurrent endometrial cancer: a nationwide cohort study in France"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3151-6299","authenticated-orcid":false,"given":"Allison","family":"Singier","sequence":"first","affiliation":[{"name":"EPIPHARE Scientific Interest Group in Epidemiology of Health Products, (French National Agency for the Safety of Medicines and Health Products-ANSM, French National Health Insurance-CNAM) , F-93285 Saint-Denis Cedex,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1292-6631","authenticated-orcid":false,"given":"St\u00e9phane","family":"Vignot","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Reims Champagne Ardennes, Institut Godinot , UR7509 Reims,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Desplas","sequence":"additional","affiliation":[{"name":"EPIPHARE Scientific Interest Group in Epidemiology of Health Products, (French National Agency for the Safety of Medicines and Health Products-ANSM, French National Health Insurance-CNAM) , F-93285 Saint-Denis Cedex,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8393-4217","authenticated-orcid":false,"given":"Mahmoud","family":"Zureik","sequence":"additional","affiliation":[{"name":"EPIPHARE Scientific Interest Group in Epidemiology of Health Products, (French National Agency for the Safety of Medicines and Health Products-ANSM, French National Health Insurance-CNAM) , F-93285 Saint-Denis Cedex,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9316-8280","authenticated-orcid":false,"given":"Nadia","family":"Haddy","sequence":"additional","affiliation":[{"name":"EPIPHARE Scientific Interest Group in Epidemiology of Health Products, (French National Agency for the Safety of Medicines and Health Products-ANSM, French National Health Insurance-CNAM) , F-93285 Saint-Denis Cedex,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"2026082009564910800_oyag316-B1","doi-asserted-by":"publisher","first-page":"e2341165","DOI":"10.1001\/JAMANETWORKOPEN.2023.41165","article-title":"Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial","volume":"6","author":"Andr\u00e9","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026082009564910800_oyag316-B2","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1056\/nejmoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"2026082009564910800_oyag316-B3","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/J.BULCAN.2023.06.009","article-title":"Real-world dostarlimab use in advanced\/recurrent endometrial cancer in France","volume":"110","author":"Rodrigues","year":"2023","journal-title":"Bull Cancer"},{"key":"2026082009564910800_oyag316-B4","doi-asserted-by":"publisher","first-page":"101903","DOI":"10.1016\/j.ijgc.2025.101903","article-title":"An ambispective, real-world multi-center study of DOstarlimab in patients with recurrent or advanced DNA mismatch repair deficient\/microsatellite instability-high endometrial cancer (GEICO 120-R\/DORA study)","volume":"35","author":"Gallego","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"2026082009564910800_oyag316-B5","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.respe.2010.04.005","article-title":"French national health insurance information system and the permanent beneficiaries sample","volume":"58","author":"Tuppin","year":"2010","journal-title":"Rev Epidemiol Sante Publique"},{"key":"2026082009564910800_oyag316-B6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40259-026-00768-y","article-title":"Real-World use of dostarlimab plus chemotherapy in advanced or recurrent endometrial cancer: a nationwide cohort study in France","volume":"40","author":"Singier","year":"2026","journal-title":"BioDrugs"},{"key":"2026082009564910800_oyag316-B7","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1186\/s12913-020-05667-8","article-title":"Access to inpatient palliative care among cancer patients in France: an analysis based on the national cancer cohort","volume":"20","author":"Janah","year":"2020","journal-title":"BMC Health Serv Res"},{"key":"2026082009564910800_oyag316-B8","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1136\/ijgc-2022-004178","article-title":"Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent\/advanced endometrial cancer: data from the GARNET trial and the national cancer registration service in England","volume":"33","author":"Goulden","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"2026082009564910800_oyag316-B9","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jama.2024.2396","article-title":"Clinical benefit and regulatory outcomes of cancer drugs receiving accelerated approval","volume":"331","author":"Liu","year":"2024","journal-title":"JAMA"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag316\/70684039\/oyag316.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag316\/70684039\/oyag316.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag316\/70684039\/oyag316.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:57:01Z","timestamp":1787234221000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag316\/8763696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":9,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag316","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,6]]},"article-number":"oyag316"}}